Racial disparities in the treatment of advanced epithelial ovarian cancer

Obstetrics and Gynecology

Volumn 122, Issue 5, 2013, Pages 1025-1032

  Howell, Elizabeth A ^a   Egorova, Natalia ^a   Hayes, Monica P ^a   Wisnivesky, Juan ^a   Franco, Rebeca ^a   Bickell, Nina ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONFERENCE PAPER; ETHNIC OR RACIAL ASPECTS; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; OBSERVATIONAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE; SURVIVAL RATE;

AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COMBINED MODALITY THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HEALTHCARE DISPARITIES; HUMANS; MEDICARE; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROPENSITY SCORE; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 84887156043     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182a92011     Document Type: Conference Paper

References (29)

1. National Cancer Institute. General Information About Ovarian Epithelial Cancer. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/ ovarianepithelial/HealthProfessional#- Section-416. Retrieved November 7, 2012.
2. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Program. Available at: http://www.seer.cancer. gov/csr/1975-2009-pops09/ browse-csr.php?section521&page5sect-21-table.08.html. Retrieved November 7, 2012.
3. Terplan M, Temkin S, Tergas A, Lengyel E. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol 2008; 111: 173-8.
4. Chan JK, Zhang M, Hu JM, Shin JY, Osann K, Kapp DS. Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol 2008;97:103-7.
5. Barnholtz-Sloan JS, Tainsky MA, Abrams J, Severson RK, Qureshi F, Jacques SM, et al. Ethnic differences in survival among women with ovarian carcinoma. Cancer 2002;94: 1886-93.
6. Bristow RE, Zahurak ML, Ibeanu OA. Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol 2011;121:364-8.
7. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol 2011;122:319-23.
8. Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer 2009;115:4210-17.
9. Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer 2008;18:660-9.
10. Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Trends in treatment of advanced epithelial ovarian cancer in the medicare population. Gynecol Oncol 2011;122: 100-6.
11. National Comprehensive Cancer Network. Practice guidelines in oncology v2. Ovarian, fallopian tube, and primary peritoneal carcinomas. Fort Washington (PA): National Comprehensive Cancer Network; 2010.
12. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002;40(Suppl 8): IV-55-61.
13. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(Suppl 8):IV-3-18.
14. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002;40(Suppl 8):IV-43-8.
15. Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CN, Begg CB. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 2002;40(Suppl 8):IV-62-8.
16. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicarelinked data. Med Care 2002;40(Suppl 8):IV-49-54.
17. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-80.
18. Arday SL, Arday DR, Monroe S, Zhang J. HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev 2000;21:107-16.
19. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database: applications and limitations. Med Care 2002;40(Suppl 8):IV-19-25.
20. Zaslavsky AM, Ayanian JZ, Zaborski LB. The validity of race and ethnicity in enrollment data for medicare beneficiaries. Health Serv Res 2012;47(3 Pt 2):1300-21.
21. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47: 1245-51.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
23. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127(8 Pt 2):757-63.
24. Ying G, Liu C. Statistical analysis of clustered data using SAS system. NorthEast SAS Users Group (NESUG) Proceedings. 2006:1-13.
25. Gharibvand L, Liu L. Analysis of survival data with clustered events. 2009 Paper 237. In: SAS Global Forum Proceedings SaDA. Vol. 482008.
26. Oakes J, Kaufman J, editors. Methods in social epidemiology. San Francisco (CA): Jon Wiley & Sons, Inc.; 2006.
27. Terplan M, Smith EJ, Temkin SM. Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes Control 2009;20:1139-50.
28. Bickell NA, LePar F, Wang JJ, Leventhal H. Lost opportunities: physician's reasons and disparities in breast cancer treatment. J Clin Oncol 2007;25:2516-21.
29. Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H. Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol 2009;27:5160-7.